APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

ESR1 Mutated Metastatic Breast Cancer Diagnostics

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Analysis and Forecast 2026-2032

Report ID 17413630022 May 2026252 pages

Choose your research edition.

Industry ResearchESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032183 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Outlook and Growth Opportunities 2026183 pages · $4,250 USDMarket Analysis & ForecastGlobal ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Analysis and Forecast 2026-2032252 pages · $4,950 USD

Market perspective

The global ESR1 Mutated Metastatic Breast Cancer Diagnostics market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for ESR1 Mutated Metastatic Breast Cancer Diagnostics is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of ESR1 Mutated Metastatic Breast Cancer Diagnostics include APIS Assay Technologies, lllumina, Inc., GENCURIX, RainSure Scientific, NeoGenomics Laboratories, Sysmex Corporation, ASURAGEN,INC and Guardant Health, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for ESR1 Mutated Metastatic Breast Cancer Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of ESR1 Mutated Metastatic Breast Cancer Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for ESR1 Mutated Metastatic Breast Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the ESR1 Mutated Metastatic Breast Cancer Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for ESR1 Mutated Metastatic Breast Cancer Diagnostics revenue, projected growth trends, production technology, application and end-user industry.

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Company

APIS Assay Technologies

lllumina, Inc.

GENCURIX

RainSure Scientific

NeoGenomics Laboratories

Sysmex Corporation

ASURAGEN,INC

Guardant Health

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Type

NGS Based

PCR Based

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Application

Hospital Associated Labs

lndependent Diagnostic Laboratories

Diagnostic Imaging Centers

Cancer Research lnstitutes

ESR1 Mutated Metastatic Breast Cancer Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global ESR1 Mutated Metastatic Breast Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of ESR1 Mutated Metastatic Breast Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of ESR1 Mutated Metastatic Breast Cancer Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of ESR1 Mutated Metastatic Breast Cancer Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, ESR1 Mutated Metastatic Breast Cancer Diagnostics revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NGS Based Major Player Table 3. PCR Based Major Player Table 4. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Associated Labs Major Player Table 6. lndependent Diagnostic Laboratories Major Player Table 7. Diagnostic Imaging Centers Major Player Table 8. Cancer Research lnstitutes Major Player Table 9. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends Table 10. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Drivers Table 11. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Opportunities and Challenges Table 12. ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Restraints Table 13. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026) & (US$ Million) Table 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2021-2026) Table 16. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2027-2032) & (US$ Million) Table 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region (2027-2032) Table 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Players (US$ Million) & (2021-2026) Table 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Players (2021-2026) Table 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Headquarters & Area Served Table 22. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Players, Product Type & Application Table 23. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 28. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 29. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2021-2026) Table 30. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2027-2032) Table 31. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 33. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 34. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2021-2026) Table 35. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2027-2032) Table 36. APIS Assay Technologies Company Information Table 37. APIS Assay Technologies Business Overview Table 38. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 40. APIS Assay Technologies Recent Development Table 41. lllumina, Inc. Company Information Table 42. lllumina, Inc. Business Overview Table 43. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 45. lllumina, Inc. Recent Development Table 46. GENCURIX Company Information Table 47. GENCURIX Business Overview Table 48. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 50. GENCURIX Recent Development Table 51. RainSure Scientific Company Information Table 52. RainSure Scientific Business Overview Table 53. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 55. RainSure Scientific Recent Development Table 56. NeoGenomics Laboratories Company Information Table 57. NeoGenomics Laboratories Business Overview Table 58. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 60. NeoGenomics Laboratories Recent Development Table 61. Sysmex Corporation Company Information Table 62. Sysmex Corporation Business Overview Table 63. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 65. Sysmex Corporation Recent Development Table 66. ASURAGEN,INC Company Information Table 67. ASURAGEN,INC Business Overview Table 68. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 70. ASURAGEN,INC Recent Development Table 71. Guardant Health Company Information Table 72. Guardant Health Business Overview Table 73. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio Table 75. Guardant Health Recent Development Table 76. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 77. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 78. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 79. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 80. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 82. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 83. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 86. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 87. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 89. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 90. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 91. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 92. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 93. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 95. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 96. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 97. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Region (US$ Million) & (2021-2026) Table 100. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Region (US$ Million) & (2027-2032) Table 101. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026) & (US$ Million) Table 102. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032) & (US$ Million) Table 103. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026) & (US$ Million) Table 104. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032) & (US$ Million) Table 105. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021-2026) & (US$ Million) Table 107. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (US$ Million) & (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. ESR1 Mutated Metastatic Breast Cancer Diagnostics Image Figure 2. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 4. NGS Based Image Figure 5. PCR Based Image Figure 6. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Associated Labs Image Figure 9. lndependent Diagnostic Laboratories Image Figure 10. Diagnostic Imaging Centers Image Figure 11. Cancer Research lnstitutes Image Figure 12. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size (US$ Million) & (2021-2032) Figure 13. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2021-2032) Figure 20. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2021-2032) Figure 23. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 25. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 26. North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 27. United States ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 32. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 33. Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 34. Germany ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 44. China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 45. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 47. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 48. Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Region (2021-2032) Figure 49. Japan ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032) Figure 57. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032) Figure 58. SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Country (2021-2032) Figure 59. Brazil ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • NGS Based
  • PCR Based
Applications
  • Hospital Associated Labs
  • lndependent Diagnostic Laboratories
  • Diagnostic Imaging Centers
  • Cancer Research lnstitutes
Companies covered
  • APIS Assay Technologies
  • lllumina, Inc.
  • GENCURIX
  • RainSure Scientific
  • NeoGenomics Laboratories
  • Sysmex Corporation
  • ASURAGEN,INC
  • Guardant Health

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Type
  3. 1.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NGS Based
  5. 1.2.3 PCR Based
  6. 1.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market by Application
  7. 1.3.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Associated Labs
  9. 1.3.3 lndependent Diagnostic Laboratories
  10. 1.3.4 Diagnostic Imaging Centers
  11. 1.3.5 Cancer Research lnstitutes
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Dynamics
  1. 2.1 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Trends
  2. 2.2 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Drivers
  3. 2.3 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Opportunities and Challenges
  4. 2.4 ESR1 Mutated Metastatic Breast Cancer Diagnostics Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Perspective (2021-2032)
  2. 3.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Growth Trends by Region
  3. 3.2.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2021-2026)
  5. 3.2.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Players
  2. 4.1.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Players (2021-2026)
  3. 4.1.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Key Players Headquarters & Area Served
  7. 4.4 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Players, Product Type & Application
  8. 4.5 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market CR5 and HHI
  11. 4.6.3 2025 ESR1 Mutated Metastatic Breast Cancer Diagnostics Tier 1, Tier 2, and Tier 3
5 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Type
  1. 5.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2032)
  3. 5.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Type (2021-2032)
6 ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size by Application
  1. 6.1 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2032)
  3. 6.3 Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 APIS Assay Technologies
  2. 7.1.1 APIS Assay Technologies Company Information
  3. 7.1.2 APIS Assay Technologies Business Overview
  4. 7.1.3 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  5. 7.1.4 APIS Assay Technologies ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  6. 7.1.5 APIS Assay Technologies Recent Developments
  7. 7.2 lllumina, Inc.
  8. 7.2.1 lllumina, Inc. Company Information
  9. 7.2.2 lllumina, Inc. Business Overview
  10. 7.2.3 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  11. 7.2.4 lllumina, Inc. ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  12. 7.2.5 lllumina, Inc. Recent Developments
  13. 7.3 GENCURIX
  14. 7.3.1 GENCURIX Company Information
  15. 7.3.2 GENCURIX Business Overview
  16. 7.3.3 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  17. 7.3.4 GENCURIX ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  18. 7.3.5 GENCURIX Recent Developments
  19. 7.4 RainSure Scientific
  20. 7.4.1 RainSure Scientific Company Information
  21. 7.4.2 RainSure Scientific Business Overview
  22. 7.4.3 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  23. 7.4.4 RainSure Scientific ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  24. 7.4.5 RainSure Scientific Recent Developments
  25. 7.5 NeoGenomics Laboratories
  26. 7.5.1 NeoGenomics Laboratories Company Information
  27. 7.5.2 NeoGenomics Laboratories Business Overview
  28. 7.5.3 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  29. 7.5.4 NeoGenomics Laboratories ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  30. 7.5.5 NeoGenomics Laboratories Recent Developments
  31. 7.6 Sysmex Corporation
  32. 7.6.1 Sysmex Corporation Company Information
  33. 7.6.2 Sysmex Corporation Business Overview
  34. 7.6.3 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Sysmex Corporation ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  36. 7.6.5 Sysmex Corporation Recent Developments
  37. 7.7 ASURAGEN,INC
  38. 7.7.1 ASURAGEN,INC Company Information
  39. 7.7.2 ASURAGEN,INC Business Overview
  40. 7.7.3 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  41. 7.7.4 ASURAGEN,INC ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  42. 7.7.5 ASURAGEN,INC Recent Developments
  43. 7.8 Guardant Health
  44. 7.8.1 Guardant Health Company Information
  45. 7.8.2 Guardant Health Business Overview
  46. 7.8.3 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Guardant Health ESR1 Mutated Metastatic Breast Cancer Diagnostics Product Portfolio
  48. 7.8.5 Guardant Health Recent Developments
8 North America
  1. 8.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (2021-2032)
  2. 8.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2032)
  3. 8.2.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026)
  4. 8.2.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032)
  5. 8.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 8.4 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2032)
  7. 8.4.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026)
  8. 8.4.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032)
  9. 8.5 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 8.6 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country
  11. 8.6.1 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021-2026)
  13. 8.6.3 North America ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (2021-2032)
  2. 9.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2032)
  3. 9.2.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026)
  4. 9.2.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032)
  5. 9.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 9.4 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2032)
  7. 9.4.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026)
  8. 9.4.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032)
  9. 9.5 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 9.6 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country
  11. 9.6.1 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021-2026)
  13. 9.6.3 Europe ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (2021-2032)
  2. 10.2 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2032)
  3. 10.2.1 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026)
  4. 10.2.2 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032)
  5. 10.3 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 10.4 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2032)
  7. 10.4.1 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026)
  8. 10.4.2 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032)
  9. 10.5 China ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (2021-2032)
  2. 11.2 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2032)
  3. 11.2.1 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026)
  4. 11.2.2 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032)
  5. 11.3 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 11.4 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2032)
  7. 11.4.1 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026)
  8. 11.4.2 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032)
  9. 11.5 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 11.6 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country
  11. 11.6.1 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021-2026)
  13. 11.6.3 Asia ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue (2021-2032)
  2. 12.2 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Type (2027-2032)
  5. 12.3 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Application (2027-2032)
  9. 12.5 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country
  11. 12.6.1 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA ESR1 Mutated Metastatic Breast Cancer Diagnostics Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst